Dr. Reddy’s Laboratories

雷迪博士实验室

on Saturday launched Obeda, a

周六推出了奥贝达，一个

semaglutide injection

司美格鲁肽注射液

for Type 2 diabetes, becoming the first Indian company to receive approval from the Drugs Controller General of India (DCGI) for a generic version of the drug.

对于2型糖尿病，成为首家获得印度药品监管总局（DCGI）批准的印度公司，获准生产该药物的仿制药版本。

The launch marks its entry into the

此次发射标志着其进入

GLP-1 receptor agonist

GLP-1受体激动剂

therapy segment from day one of patent expiry, the company said in a regulatory filing.

从专利到期的第一天起，治疗领域就开始了，该公司在监管文件中表示。

Obeda is available in 2 mg and 4 mg strengths in a pre-filled disposable pen for once-a-week subcutaneous administration. Each pen delivers a minimum of four weekly doses, with the therapy priced at Rs 4,200 per month for both strengths.

奥贝达有2毫克和4毫克两种规格，采用预填充一次性注射笔，每周一次皮下注射。每支注射笔可提供至少四周的剂量，两种规格的治疗每月价格均为4200卢比。

Also read:

另请阅读：

Semaglutide patent expiry: India’s next big public health inflection point

司美鲁肽专利到期：印度下一个重要的公共卫生转折点

In a Phase III study involving 312 participants, the drug demonstrated non-inferior efficacy and a safety profile comparable to the innovator drug, with similar outcomes in glycaemic control and related measures.

在一项涉及312名参与者的III期研究中，该药物表现出与原研药相当的非劣效性和相似的安全性，在血糖控制及相关指标上结果相近。

Live Events

现场活动

The company said development and manufacturing of the drug, including the active pharmaceutical ingredient and formulation, were carried out in-house.

公司表示，该药物的开发和生产，包括活性药物成分和配方，都是在内部进行的。

Dr. Reddy’s added it plans to introduce

博士伦公司补充说，它计划推出

generic semaglutide

通用司美格鲁肽

in multiple countries, subject to regulatory approvals.

在多个国家，视监管审批而定。

'Today’s launch marks a significant step in our commitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patients in India and across global markets. Our foray into GLP-1 therapies reflects our capabilities in complex product development and peptide science,' Erez Israeli, Chief Executive Officer of Dr.

“今天的发布标志着我们在承诺扩大在关键治疗领域的产品组合方面迈出了重要一步，为印度及全球市场的患者提供差异化解决方案。我们进军GLP-1疗法反映了我们在复杂产品开发和肽科学方面的能力。” Dr. 的首席执行官埃雷兹·以色列利说。

Reddy’s, said..

雷迪说。

'As part of phase-1 launch, we aim to introduce generic semaglutide in several countries and, through our ‘One Product, One Quality’ approach, we are committed to ensure the same high‑quality product across all markets, Israeli added.

“作为第一阶段发布的一部分，我们旨在多个国家推出通用版司美鲁肽，并且通过我们的‘一个产品，一个质量’方法，我们致力于确保所有市场上的产品质量保持一致的高标准，”以色列补充道。

The country’s most definitive MSME stage returns on March 24 in New Delhi. Register now for the ET MSME Awards 2025

印度最具权威的中小微企业盛会将于3月24日在新德里回归。立即注册参加2025年《经济时报》中小微企业奖。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)